Natural Capsules Limited (NATCAPSUQ) fundamentals
Natural Capsules Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as NATCAPSUQ (ISIN INE936B01015). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Natural Capsules Limited does
Natural Capsules Limited is an India-based hard capsule shell manufacturer, specialized in manufacturing an array of capsules, including hard gelatin capsules, vegetarian capsules, and various specialty variants. The Company offers a diverse range of capsule products to both domestic and international markets, serving the pharmaceutical and nutraceutical industries. Its offerings include hard gelatin capsules, hydroxypropyl methylcellulose (HPMC) vegetarian capsules and others, including shiny capsules, sweet capsules, fast-release capsules, regulatory variants, sodium laureth sulfate (SLS) free capsules, preservative free capsules and transmissible spongiform encephalopathy (TSE) free capsules. The Company, through its subsidiary, Natural Biogenex Private Limited, is focused on manufacturing APIs such as prednisolone, betamethasone, dexamethasone, and hydrocortisone along with their derivatives. It has two manufacturing facilities that are located in Bengaluru and Puducherry.
Valuation and market data
| Last close | ₹188.70 |
|---|---|
| Market capitalisation | ₹195 crore |
| Enterprise value | ₹252 crore |
| P/E (TTM) | 0.00 |
| Price to book | 0.83 |
| Price to sales (TTM) | 0.61 |
| Book value per share | ₹226.91 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Feb 14 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹181 crore | ₹15 crore | ₹11 crore | 10.79 |
| Mar 2025 | ₹172 crore | ₹9 crore | ₹7 crore | 6.43 |
| Mar 2024 | ₹157 crore | ₹10 crore | ₹8 crore | 8.67 |
| Mar 2023 | ₹174 crore | ₹26 crore | ₹19 crore | 20.68 |
| Mar 2022 | ₹136 crore | ₹19 crore | ₹14 crore | 19.62 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 50.9% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 49.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.